A B S T R A C T In this study we further characterize the properties of the prostaglandin-producing suppressor cell. Overnight preincubation of peripheral blood mononuclear cells results in an increased response of the cells to phytohemagglutinin or Concanavalin A compared to the response of fresh cells. This increase in mitogen response with preincubation was similar in magnitude to the increase in mitogen response of fresh cells after the addition of indomethacin. The two manipulations were not additive; that is, after preincubation, indomethacin caused much less enhancement of mitogen stimulation of peripheral blood mononuclear cells (100±12% increase before preincubation vs. 12±+6% after preincubation; mean-+-SEM, P < 0.001).
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Preincubated cells also lose sensitivity to inhibition by exogenous prostaglandin E2. It requires the addition of 100-to >1,000-fold more exogenous PGE2 to produce comparable inhibition of phytohemagglutininstimulated preincubated cells than is required for inhibition of phytohemagglutinin-stimulated fresh cells.
The enhancing effect of indomethacin increases with decreasing doses of phytohemagglutinin. Indomethacin causes a 1,059+134% increase in [3H]thymidine incorporation at the lowest dose of phytohemagglutinin (0.2 ,ug/ml), and a 4+3% increase at the highest dose (20 ,ug/ml) . This increase in response to indomethacin with a lower dose of phytohemagglutinin is due to increased sensitivity to inhibition by PGE2 at lower mitogen doses. INTRODUCTION The role of suppressor cells in the regulation of humoral and cellular immunity has received much attention in this decade. Investigators employing animal models have identified suppressor cells that influence many aspects ofT-and B-cell function (1) . Furthermore, T-cell (2), B-cell (3), and macrophage (4) subpopulations have been implicated as suppressor cells. These cells have been suggested as etiologic or contributory in the pathogenesis of several diseases, including common variable hypogammaglobulinemia (5) , immunoglobulin A (IgA) deficiency (6) , multiple myeloma (7), Hodgkin's disease (8) (9) (10) , and systemic lupus erythematosus (11) . Human suppressor cell activity was shown by adding circulating lymphocytes from patients with those diseases to normal lymphocytes and demonstrating an inhibition of various in vitro T-and B-cell functional assays.
More recently, several groups have reported on assays for suppressor cells in peripheral blood mononuclear cells (PBMC)1 in normal humans. Shou et al. (12) and Hubert et al. (13) have described a concanavalin A (Con A)-activated suppressor cell in normal humans similar to the cell described by Waksman and his co-workers in mice (2, 14) . This assay involves stimulating normal lymphocytes with Con A for 24 h, then adding them to fresh mitogen-stimulated or mixed lymphocyte cultures from the same or a different donor. The "prestimulated" cells cause a 20-50% inhibition in the subsequent cultures. Bresnihan and Jasin (11) described a "short-lived suppressor cell" in normal peripheral blood. They found that lymphocytes preincubated overnight in media alone responded better to suboptimal doses of T-cell mitogens than did fresh lymphocytes. They ascribed this increase in reactivity to the death or deactivation of a "short-lived suppressor cell."
We have described a prostaglandin (PG)-producing suppressor cell that inhibits human lymphocyte activation by T-cell mitogens in vitro (15 (10) . Addition of PG synthetase inhibitors eliminates this production and restores the depressed mitogen response to normal.
In the present study, we further characterize the properties of the PG-producing suppressor cell. It appears that the PG-producing suppressor cell assay and the short-lived suppressor cell assay measure overlapping phenomena.
METHODS
Subjects. 15 Plastics, Div. BioQuest, Oxnard, Calif.), 2 x 106 cells in 1 ml of media per tube. These suspensions were combined and washed twice with PBS after overnight incubation. They were then prepared in the culture plates as described above. The filters were counted in a liquid scintillation counter. All cultures were performed in sextuplicate. Net counts per minute (cpm) were calculated as cpm of cells plus mitogen plus drug (PG, indomethacin, or nothing) minus cpm of cells plus drug. Percent stimulation of [3H]thymidine incorporation was calculated by dividing the net cpm of the mitogen cultures with indomethacin by the net cpm of the mitogen cultures without indomethacin. This number was expressed as a percent and 100% was subtracted from it to obtain percent stimulation. Percent inhibition of [3H]thymidine incorporation caused by PGE was calculated by dividing the net cpm of the mitogen cultures with PGE by the net cpm of the mitogen cultures without PGE. The fraction was expressed as a percent and subtracted from 100% to obtain percent inhibition. Whenever we measured the inhibiting effect of exogenously added PGE2, we also added indomethacin (1 ,ug/ml) to those cultures to remove the confounding variable of endogenously produced PGs (14) . The lots of PHA, Con A, and FCS used in these experiments were different from those used in our previous reports (10, 14) .
Measurement of PG production in cultures. Cell suspensions (5 x 105 per ml in minimal essential medium with 20% FCS) were prepared as described above and 1-ml aliquots were incubated in 1 x 7.5-cm round-bottom plastic tubes with PHA in varying concentrations. A blank assay consisting of minimal essential medium and 20% FCS without cells was also established. These tubes were then placed in a 5% CO2 incubator at 37°C. At various times thereafter, duplicate tubes were withdrawn, the cells resuspended, and then centrifuged at 400 g for 10 min. The supernates were then withdrawn for measurement of "total PG" and of PGE2. The assay for PG was performed as previously described (10, 15, 16) , using an antiserum that recognized both PGE and PGA (10) . The cell supernates were extracted for PG determination by previously described methods (16 
RESULTS
Comparison of indomethacin and preincubation on the response of leukocytes. We first investigated whether indomethacin and preincubation had similar quantitative effects on the mitogen response. As shown in Fig. 1 , both treatments increased the response to a suboptimal dose ofCon A (1 jig/ml). The increases were essentially equal. To determine whether indomethacin and preincubation affected similar cells, indomethacin was added to preincubated cells. The enhancing effects of the two procedures were not additive ( Table I ). The increase obtained with both was usually no greater than that seen with the addition of indomethacin to fresh cells. In 10 experiments at various PHA concentrations, addition of indomethacin to fresh cells caused a 100+12% increase in [3H]thymidine incorporation; this fell to a 12±6% increase when indomethacin was added to cells that had been preincubated in the microtiter plates overnight (mean ±SEM, P < 0.001). To control for the possible effect of an accumulated metabolite in the preincubated cultures, we also preincubated leukocytes overnight and then washed them twice in PBS before putting them in the culture plates. These preincubated and washed cells also were significantly less enhanced by the addition of indomethacin (20±12% increase, P < 0.001). § Mean percent increase in cpm of the subjects tested. At 5 ug/ml Con A and at 10 ug/ml PHA, the mean percent increase caused by both preincubation and addition of indomethacin was no greater than the increase caused by indomethacin alone.
At 1 gg/ml Con A, the mean increase with both treatments was higher than that with indomethacin alone, but this difference was not significant (t = 1.31, P > 0.2 by two-tailed t test).
Prostaglandin by 24 h. It is also clear from this figure that indomethacin causes greater enhancement of cultures with lower concentrations of PHA. As in our previous studies (10, 15) , the effects of RO-20-5720, a PG synthetase inhibitor chemically unrelated to indomethacin (17) , were similar to the effects of indomethacin mentioned above.
One possible explanation for the loss of sensitivity to indomethacin with preincubation is that preincubation shifts the kinetics of the PHA Prostaglandin production in mitogen cultures. Two possible explanations for the loss of enhancing effect of indomethacin after preincubation of cells are apparent. First, the PG-producing suppressor cell could be "short-lived" and stop producing PGE2. Second, the cells normally inhibited by the endogenously produced PGE2 could become refractory to its inhibiting action. To examine the first possibility, we measured production of PGE2 in PHA-stimulated cultures over a 48-h period. The data presented in Fig. 3 demonstrate that both PGE and total PG (PGE plus PGA) accumulate over time in mitogen cultures. Thus the PG-producing suppressor cell is still active after 24 h of incubation. Inasmuch as it is probable that the PGA accumulated in cell cultures is a nonenzymatic breakdown product of PGE (18) , the total PG production might be a closer estimate of the PGE produced in the culture (18, 19) . Table III presents data on PG production in cultures of PBMC as a function of PHA concentration. Total PG and PGE2 production both increase with increasing doses of PHA. PBMC cultured without the addition of PHA still produce an appreciable amount of PG. Cultures of PBMC without PHA accumulate PGE and total PG over time in a manner parallel to that shown in Fig. 3 for cultures with PHA.
Loss ofsensitivity to PGE2 after preincubation. We next examined the effect of exogenous PGE2 on mitogen stimulation of fresh vs. preincubated leukocytes. As shown in Table IV , after overnight incubation PHAstimulated leukocytes are much less sensitive to the inhibiting effects of exogenous PGE2. It required 100-to 1,000-fold higher amounts of exogenous PGE2 in cultures of preincubated cells to achieve levels of in- hibition obtained in cultures offresh cells. Fig. 4 graphs the loss of sensitivity to PGE2 in PHA cultures as a function of time of preincubation. PBMC rapidly lose their susceptibility to inhibition by PGE2 with preincubation. These curves for inhibition by PGE2 as a function of time of preincubation are similar to the curves for enhancement by indomethacin as a function of time of preincubation (Fig. 2) . The above data would suggest that although the PGproducing suppressor cell acts as it if were "shortlived," in actuality the responding population of cells has short-lived suppressibility. This loss of sensitivity of cells to PGE2 would appear to be an active process, for preincubation of cells overnight at room tempera- Prostaglandin Suppression of Mitogen-Stimulated Lymphocytes (20) . The earlier reports used optimal doses of mitogens whereas we have employed slightly suboptimal levels. As shown in Fig. 2 (Table III) . Other work in our laboratory has identified the PG-producing suppressor cell as a monocyte or macrophage, using double labeling experiments with fluorescein-tagged anti-PGE2 antibodies and ingestion of polystyrene beads.3 This cell apparently is capable of a substantial unstimulated PGE2 production, which then increases when increasing concentrations of PHA are added. But while PGE2 production increases, sensitivity to PGE2 decreases with increasing PHA concentrations, so that, in balance, PGE2 plays a greater role in cultures stimulated with small amounts of PHA.
Over the past several years, several other suppressor cell systems have been described in experimental animals and man. It is possible and perhaps even likely 2 that some of these systems work through PGE2 production. The Con A-activated suppressor cell described in animals by Pierce and co-workers (22) and also by Waksman et al. (2, 14) is also present in humans (12, 13) . We have found that this cell does not work via PG synthesis in humans (15) . This is in keeping with findings in experimental animals describing a glycoprotein as the mediator for this cell (14) . On the other hand, Stobo et al. (23) has described a circulating suppressor cell in the peripheral blood of some patients with chronic fungal diseases. The macrophages ofthese patients liberate a soluble material that will suppress the mitogen response of normal cells. Preincubation of either normal or patient cells renders them insensitive to the suppressing effects of this soluble material (24) . Thus, this suppressor cell behaves similarly to the PGproducing suppressor cell. Baird and Kaplan (25) have studied the suppression of mitogen cultures by macrophages in mice. This suppression is also mediated through a soluble substance (26) . Olding et al. (27) have recently reported that fetal cells secrete a dializable substance that suppresses the response of maternal lymphocytes to mitogens. These mediators have not been identified, but the possibility that they could be PGE2 should be investigated.
